ATAIBECKLEY INC (9VC.DE) Fundamental Analysis & Valuation

FRA:9VC • NL0015000DX5

3.426 EUR
-0.04 (-1.21%)
Last: Dec 30, 2025, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This 9VC.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

Taking everything into account, 9VC scores 3 out of 10 in our fundamental rating. 9VC was compared to 49 industry peers in the Pharmaceuticals industry. 9VC has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, 9VC is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

0

1. 9VC.DE Profitability Analysis

1.1 Basic Checks

  • 9VC had negative earnings in the past year.
  • In the past year 9VC has reported a negative cash flow from operations.
  • 9VC had negative earnings in each of the past 5 years.
  • 9VC had a negative operating cash flow in each of the past 5 years.
9VC.DE Yearly Net Income VS EBIT VS OCF VS FCF9VC.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -62.24%, 9VC is doing worse than 83.64% of the companies in the same industry.
  • With a Return On Equity value of -93.44%, 9VC is not doing good in the industry: 80.00% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -62.24%
ROE -93.44%
ROIC N/A
ROA(3y)-52.42%
ROA(5y)-70.02%
ROE(3y)-67.79%
ROE(5y)-86.99%
ROIC(3y)N/A
ROIC(5y)N/A
9VC.DE Yearly ROA, ROE, ROIC9VC.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for 9VC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
9VC.DE Yearly Profit, Operating, Gross Margins9VC.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -20K -40K -60K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. 9VC.DE Health Analysis

2.1 Basic Checks

  • 9VC does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • 9VC has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, 9VC has more shares outstanding
  • The debt/assets ratio for 9VC is higher compared to a year ago.
9VC.DE Yearly Shares Outstanding9VC.DE Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M 150M
9VC.DE Yearly Total Debt VS Total Assets9VC.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • 9VC has an Altman-Z score of 5.29. This indicates that 9VC is financially healthy and has little risk of bankruptcy at the moment.
  • 9VC's Altman-Z score of 5.29 is fine compared to the rest of the industry. 9VC outperforms 76.36% of its industry peers.
  • 9VC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.29
ROIC/WACCN/A
WACC7.43%
9VC.DE Yearly LT Debt VS Equity VS FCF9VC.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 7.90 indicates that 9VC has no problem at all paying its short term obligations.
  • 9VC has a better Current ratio (7.90) than 98.18% of its industry peers.
  • 9VC has a Quick Ratio of 7.90. This indicates that 9VC is financially healthy and has no problem in meeting its short term obligations.
  • 9VC has a Quick ratio of 7.90. This is amongst the best in the industry. 9VC outperforms 98.18% of its industry peers.
Industry RankSector Rank
Current Ratio 7.9
Quick Ratio 7.9
9VC.DE Yearly Current Assets VS Current Liabilites9VC.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. 9VC.DE Growth Analysis

3.1 Past

  • 9VC shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.
  • The Revenue has decreased by -1.91% in the past year.
  • 9VC shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -75.28% yearly.
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-75%
Revenue 1Y (TTM)-1.91%
Revenue growth 3Y-75.28%
Revenue growth 5YN/A
Sales Q2Q%1772.5%

3.2 Future

  • Based on estimates for the next years, 9VC will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.08% on average per year.
  • The Revenue is expected to grow by 234.05% on average over the next years. This is a very strong growth
EPS Next Y30.67%
EPS Next 2Y22.22%
EPS Next 3Y14.8%
EPS Next 5Y14.08%
Revenue Next Year468.25%
Revenue Next 2Y-38.09%
Revenue Next 3Y24.11%
Revenue Next 5Y234.05%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
9VC.DE Yearly Revenue VS Estimates9VC.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B 2.5B
9VC.DE Yearly EPS VS Estimates9VC.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 4

More info and screens

Find the best growth stocksShow best growing peers

0

4. 9VC.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for 9VC. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for 9VC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
9VC.DE Price Earnings VS Forward Price Earnings9VC.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
9VC.DE Per share data9VC.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

  • 9VC's earnings are expected to grow with 14.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.22%
EPS Next 3Y14.8%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. 9VC.DE Dividend Analysis

5.1 Amount

  • 9VC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

9VC.DE Fundamentals: All Metrics, Ratios and Statistics

ATAIBECKLEY INC

FRA:9VC (12/30/2025, 7:00:00 PM)

3.426

-0.04 (-1.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12
Earnings (Next)03-16
Inst Owners12.45%
Inst Owner ChangeN/A
Ins Owners3.7%
Ins Owner ChangeN/A
Market Cap1.24B
Revenue(TTM)308.00K
Net Income(TTM)-149.27M
Analysts83.33
Price Target10.49 (206.19%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-74.59%
Min EPS beat(2)-131.54%
Max EPS beat(2)-17.64%
EPS beat(4)1
Avg EPS beat(4)-48.58%
Min EPS beat(4)-131.54%
Max EPS beat(4)17.15%
EPS beat(8)3
Avg EPS beat(8)-34.15%
EPS beat(12)6
Avg EPS beat(12)-5.69%
EPS beat(16)8
Avg EPS beat(16)-13.8%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.74%
PT rev (3m)7.46%
EPS NQ rev (1m)-0.13%
EPS NQ rev (3m)-1.83%
EPS NY rev (1m)0%
EPS NY rev (3m)-29.5%
Revenue NQ rev (1m)-11.11%
Revenue NQ rev (3m)18.52%
Revenue NY rev (1m)-0.06%
Revenue NY rev (3m)29.19%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4703.25
P/FCF N/A
P/OCF N/A
P/B 9.07
P/tB 9.26
EV/EBITDA N/A
EPS(TTM)-0.7
EYN/A
EPS(NY)-0.4
Fwd EYN/A
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS0
BVpS0.38
TBVpS0.37
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -62.24%
ROE -93.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-52.42%
ROA(5y)-70.02%
ROE(3y)-67.79%
ROE(5y)-86.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1203.88%
Cap/Sales 3521.75%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.9
Quick Ratio 7.9
Altman-Z 5.29
F-Score4
WACC7.43%
ROIC/WACCN/A
Cap/Depr(3y)268.35%
Cap/Depr(5y)673.01%
Cap/Sales(3y)220.74%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-75%
EPS Next Y30.67%
EPS Next 2Y22.22%
EPS Next 3Y14.8%
EPS Next 5Y14.08%
Revenue 1Y (TTM)-1.91%
Revenue growth 3Y-75.28%
Revenue growth 5YN/A
Sales Q2Q%1772.5%
Revenue Next Year468.25%
Revenue Next 2Y-38.09%
Revenue Next 3Y24.11%
Revenue Next 5Y234.05%
EBIT growth 1Y18.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.8%
EBIT Next 3Y-18.5%
EBIT Next 5Y-6.5%
FCF growth 1Y3.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.22%
OCF growth 3YN/A
OCF growth 5YN/A

ATAIBECKLEY INC / 9VC.DE FAQ

What is the ChartMill fundamental rating of ATAIBECKLEY INC (9VC.DE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to 9VC.DE.


What is the valuation status for 9VC stock?

ChartMill assigns a valuation rating of 0 / 10 to ATAIBECKLEY INC (9VC.DE). This can be considered as Overvalued.


What is the profitability of 9VC stock?

ATAIBECKLEY INC (9VC.DE) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for 9VC stock?

The Earnings per Share (EPS) of ATAIBECKLEY INC (9VC.DE) is expected to grow by 30.67% in the next year.